Compare Fubotv Inc (FUBO) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fubotv Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? Fubotv Inc trades at $8.22 (market cap $901.97M), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $5.02B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 5.6× Fubotv Inc's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, Fubotv Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Fubotv Inc for 35 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| FUBO | TVTX | |
|---|---|---|
Market Cap | $901.97M | $5.02B |
Volume | 1,439,905 | 2,060,842 |
Sector | Media | Health |
52-Week High | $48.96 | $67.52 |
52-Week Low | $8.09 | $26.79 |
Typical Hold Time | 35 Days | 0 Days |
Enterprise Value | $1.07B | $5.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FUBO stock trades at $8.19, down 6.29% today, reflecting a bearish technical signal. Revenue grew to $1.62 billion in 2024, with net losses narrowing to -$172.25 million, indicating improving profitability trends. The company recently expanded sports streaming partnerships, including a multi-year NHL deal announced September 28, 2026, to enhance content offerings.
The outlook is mixed; deep undervaluation metrics like P/S of 0.16 and analyst consensus price target of $63.38 suggest significant upside, but persistent cash burn and competitive pressures in streaming pose risks. Investor sentiment hinges on execution of Disney-backed turnaround plans targeting $300 million EBITDA by FY28.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Fubotv Inc
FuboTV Inc is a sports-first, live TV streaming company, offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, fuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. The company offer subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality best suited to their preferences. The operating segments of the group are Streaming and Online wagering, of which a majority of revenue is derived from the Streaming segment. It has a business presence in the U.S. and other international countries.
Read more on FUBO →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
